[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Sablina AA, Chumakov PM, Kopnin BP: Tumor suppressor p53 and its homologue p73alpha affect cell migration. J Biol Chem; 2003 Jul 25;278(30):27362-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The decreased motility of p53-deficient cells was observed in different cell contexts: human foreskin fibroblasts (BJ), human colon and lung carcinoma cell lines (HCT116 and H1299, respectively), as well as mouse normal fibroblasts from lung and spleen, peritoneal macrophages, and keratinocytes.
  • [MeSH-major] DNA-Binding Proteins / physiology. Nuclear Proteins / physiology. Tumor Suppressor Protein p53 / physiology
  • [MeSH-minor] Animals. Blotting, Western. Cell Movement. Cells, Cultured. Collagen / pharmacology. Culture Media, Conditioned / pharmacology. DNA Damage. Drug Combinations. Enzyme Inhibitors / pharmacology. Fibroblasts / metabolism. Genes, Tumor Suppressor. Green Fluorescent Proteins. Humans. Inflammation. Laminin / pharmacology. Luminescent Proteins / metabolism. Macrophages / metabolism. Mice. Mice, Inbred C57BL. Protein Structure, Tertiary. Proteoglycans / pharmacology. Signal Transduction. Time Factors. Transcription, Genetic. Tumor Cells, Cultured. Tumor Suppressor Proteins. Up-Regulation. Wound Healing

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12750388.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / DNA-Binding Proteins; 0 / Drug Combinations; 0 / Enzyme Inhibitors; 0 / Laminin; 0 / Luminescent Proteins; 0 / Nuclear Proteins; 0 / Proteoglycans; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73; 119978-18-6 / matrigel; 147336-22-9 / Green Fluorescent Proteins; 9007-34-5 / Collagen
  •  go-up   go-down


2. Su Y, Sun CM, Chuang HH, Chang PT: Studies on the cytotoxic mechanisms of ginkgetin in a human ovarian adenocarcinoma cell line. Naunyn Schmiedebergs Arch Pharmacol; 2000 Jul;362(1):82-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxic effects of ginkgetin, a natural biflavone isolated from Selaginella moellendorffii Hieron, were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in three different human cell lines: ovarian adenocarcinoma (OVCAR-3), cervical carcinoma (HeLa) and foreskin fibroblast (FS-5).
  • Moreover, the involvement of caspase(s) in ginkgetin-induced apoptosis was demonstrated by the activation of caspase 3 after drug treatment and the suppression of cell death by a broad-spectrum caspase inhibitor, benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (z-VAD-fmk).
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents, Phytogenic / toxicity. Biflavonoids. Flavonoids / toxicity. Ovarian Neoplasms / pathology
  • [MeSH-minor] Apoptosis / drug effects. Caspase Inhibitors. Caspases / metabolism. Cell Survival / drug effects. DNA / analysis. DNA / isolation & purification. DNA Damage. Electrophoresis, Polyacrylamide Gel. Enzyme Inhibitors / pharmacology. Female. Humans. Hydrogen Peroxide / metabolism. Oxidants / metabolism. Oxidative Stress / drug effects. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10935537.001).
  • [ISSN] 0028-1298
  • [Journal-full-title] Naunyn-Schmiedeberg's archives of pharmacology
  • [ISO-abbreviation] Naunyn Schmiedebergs Arch. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biflavonoids; 0 / Caspase Inhibitors; 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / Oxidants; 481-46-9 / ginkgetin; 9007-49-2 / DNA; BBX060AN9V / Hydrogen Peroxide; EC 3.4.22.- / Caspases
  •  go-up   go-down


3. Buechner SA: Common skin disorders of the penis. BJU Int; 2002 Sep;90(5):498-506
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diseases of the male genitalia range from infectious lesions to inflammatory and neoplastic conditions, including many genital manifestations of more general skin diseases.
  • This review highlights the clinical features, diagnosis and treatment of the most common dermatoses of the male genitalia.
  • The most common causal agents for condyloma acuminatum are low-risk HPV 6 and 11; high-risk HPV types 16 and 18 are associated with premalignant and malignant lesions.
  • Imiquimod, a new topical immunotherapeutic agent, which induces interferon and other cytokines, has the potential to be a first-line therapy for genital warts.
  • Oral ivermectin, a highly active antiparasitic drug, is likely to be the treatment of choice, but until approval is granted it should be reserved for special forms of scabies.
  • Lichen sclerosus is a chronic inflammatory disease that occurs as atrophic white patches on the glans penis and foreskin.
  • The penile form is a common cause of phimosis in uncircumcised men; involvement of the urethral meatus may lead to progressive meatal stenosis.
  • Squamous cell carcinoma (SCC) in situ, e.g. erythroplasia of Queyrat and Bowen's disease, cannot be excluded clinically; their apparent clinical benignity may lead to lengthy periods of misdiagnosis and biopsy is required to confirm the diagnosis.
  • [MeSH-major] Penile Diseases. Skin Diseases
  • [MeSH-minor] Balanitis / diagnosis. Balanitis / therapy. Humans. Male. Mite Infestations / diagnosis. Mite Infestations / therapy. Penile Neoplasms / diagnosis. Penile Neoplasms / therapy. Skin Diseases, Parasitic / diagnosis. Skin Diseases, Parasitic / therapy. Skin Diseases, Viral / diagnosis. Skin Diseases, Viral / therapy


Advertisement
4. Tyagi A, Singh RP, Agarwal C, Siriwardana S, Sclafani RA, Agarwal R: Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis; 2005 Nov;26(11):1978-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells.
  • Resveratrol is one of the most extensively studied cancer chemopreventive agents; however, its mechanisms of action are not completely understood.
  • Here, we observed that resveratrol induces S phase arrest via Tyr15 phosphorylation of Cdc2 in human ovarian carcinoma Ovcar-3 cells.
  • In additional studies assessing whether observed effects of resveratrol are specific to Ovcar-3 cells, we observed that it also induces S phase arrest and H2A.X (Ser139) phosphorylation in other ovarian cancer cell lines PA-1 and SKOV-3, albeit at different levels; whereas, resveratrol showed only marginal S phase arrest in normal human foreskin fibroblasts with undetectable level of phospho-H2A.X (Ser139).
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. CDC2 Protein Kinase / metabolism. Ovarian Neoplasms / drug therapy. S Phase / drug effects. Signal Transduction / drug effects. Stilbenes / pharmacology. Tyrosine / metabolism. cdc25 Phosphatases / metabolism
  • [MeSH-minor] Ataxia Telangiectasia / metabolism. Ataxia Telangiectasia Mutated Proteins. Cell Cycle Proteins / metabolism. Checkpoint Kinase 2. DNA-Binding Proteins / metabolism. Female. Humans. Phosphorylation / drug effects. Protein Kinases / metabolism. Protein-Serine-Threonine Kinases / metabolism. Ribonucleotide Reductases / antagonists & inhibitors. Tumor Cells, Cultured. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. RESVERATROL .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15975956.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA046934; United States / NCI NIH HHS / CA / CA64514
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Stilbenes; 0 / Tumor Suppressor Proteins; 42HK56048U / Tyrosine; EC 1.17.4.- / Ribonucleotide Reductases; EC 2.7.- / Protein Kinases; EC 2.7.1.11 / Checkpoint Kinase 2; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / ATR protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / CHEK2 protein, human; EC 2.7.11.1 / Checkpoint kinase 1; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.22 / CDC2 Protein Kinase; EC 3.1.3.48 / cdc25 Phosphatases; Q369O8926L / resveratrol
  •  go-up   go-down


5. Ocker M, Alajati A, Ganslmayer M, Zopf S, Lüders M, Neureiter D, Hahn EG, Schuppan D, Herold C: The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol; 2005 Jun;131(6):385-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment for advanced stages of hepatocellular carcinoma (HCC) remains unsatisfactory.
  • HepG2, Hep1B and MH-7777A hepatoma cell lines and human foreskin fibroblasts as non-transformed controls were incubated with 5-FU, irinotecan and SAHA either alone or in combination.
  • While the single agents did not show any effects on growth of the cell lines, the combination of 5-FU and irinotecan (both 10 microM) led to a moderate increase in apoptosis and proliferation inhibition.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. Carcinoma, Hepatocellular / drug therapy. Enzyme Inhibitors / pharmacology. Histone Deacetylase Inhibitors. Hydroxamic Acids / pharmacology. Liver Neoplasms / drug therapy
  • [MeSH-minor] Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Caspase 3. Caspase 8. Caspases / metabolism. Down-Regulation. Drug Synergism. Enzyme Activation / drug effects. Fibroblasts / cytology. Fibroblasts / drug effects. Fibroblasts / metabolism. Fluorouracil / administration & dosage. Humans. Membrane Potentials / drug effects. Mitochondria / drug effects. Mitochondria / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Skin / cytology. Skin / drug effects. Skin / metabolism. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. Vorinostat .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2001 Dec 17;20(24):6969-78 [11742974.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9 [10954755.001]
  • [Cites] Clin Pharmacokinet. 1989 Apr;16(4):215-37 [2656050.001]
  • [Cites] J Hepatol. 2002 Feb;36(2):233-40 [11830335.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):912-20 [10679662.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5165-70 [11016644.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14 ):3717-21 [10919639.001]
  • [Cites] Annu Rev Biochem. 1993;62:385-427 [8102521.001]
  • [Cites] Biochem Pharmacol. 1998 Mar 1;55(5):667-76 [9515577.001]
  • [Cites] J Hepatol. 2000;32(1 Suppl):225-37 [10728807.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):576-81 [12056708.001]
  • [Cites] Biochem Pharmacol. 1998 Nov 15;56(10 ):1315-22 [9825730.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 1;88(9):3671-5 [2023917.001]
  • [Cites] Oncologist. 2001;6(1):66-80 [11161230.001]
  • [Cites] J Biol Chem. 2001 Sep 28;276(39):36734-41 [11473107.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11700-5 [12189205.001]
  • [Cites] Nat Rev Drug Discov. 2002 Apr;1(4):287-99 [12120280.001]
  • [Cites] J Pathol. 1999 Apr;187(5):567-72 [10398123.001]
  • [Cites] J Gastroenterol Hepatol. 1997 Oct;12(9-10):S319-28 [9407353.001]
  • [Cites] J Biol Chem. 1999 Dec 3;274(49):34940-7 [10574969.001]
  • [Cites] Cancer. 2001 Jan 1;91(1):101-5 [11148565.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(5):440-4 [9054958.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Feb;12(2):111-26 [9692685.001]
  • [Cites] Blood. 2001 Jan 15;97(2):502-8 [11154229.001]
  • [Cites] Ann Oncol. 2002 Dec;13(12 ):1841-51 [12453851.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12579-89 [12556448.001]
  • [Cites] Am J Hematol. 2001 Nov;68(3):170-8 [11754398.001]
  • [Cites] Int J Cancer. 2002 May 10;99(2):292-8 [11979447.001]
  • [Cites] J Cell Biol. 1997 Jul 28;138(2):449-69 [9230085.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1210-6 [10922406.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):729-34 [9398054.001]
  • [Cites] Rev Gastroenterol Disord. 2003 Winter;3(1):8-24 [12684589.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):330-8 [12724731.001]
  • (PMID = 15754201.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Proto-Oncogene Proteins c-bcl-2; 0H43101T0J / irinotecan; 58IFB293JI / vorinostat; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


6. Latimer JJ, Nazir T, Flowers LC, Forlenza MJ, Beaudry-Rodgers K, Kelly CM, Conte JA, Shestak K, Kanbour-Shakir A, Grant SG: Unique tissue-specific level of DNA nucleotide excision repair in primary human mammary epithelial cultures. Exp Cell Res; 2003 Nov 15;291(1):111-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nucleotide excision repair (NER) is a major pathway responsible for remediation of damage caused by UV light, bulky adducts, and cross-linking agents.
  • We established primary cultures of peripheral blood lymphocytes (PBLs: N = 33) and foreskin fibroblasts (FF: N = 6), as well as adult breast tissue (N = 22) using a unique culture system, and measured their NER capacity using the unscheduled DNA synthesis (UDS) functional assay.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14597413.001).
  • [ISSN] 0014-4827
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R29 CA071894; United States / NCI NIH HHS / CA / R29 CA071894-03; United States / NCI NIH HHS / CA / CA 71894-01A1
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA
  • [Other-IDs] NLM/ NIHMS271020; NLM/ PMC4729389
  •  go-up   go-down


7. Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, Hahn EG, Herold C, Schuppan D: Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut; 2005 Sep;54(9):1298-308
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: Pancreatic cancer remains a devastating diagnosis with only limited therapeutic options.
  • METHODS: siRNAs targeting two different regions in the bcl-2 gene were transfected to YAP C and DAN G pancreatic carcinoma cells and human foreskin fibroblasts.
  • Antiproliferative and proapoptotic effects were observed in tumour cells but not in fibroblasts or non-malignant tissues. siRNA permutations and diverse overhangs influenced gene silencing efficacy. siRNA was quickly distributed to all organs and excreted via the kidney and liver.
  • Bcl-2 specific siRNA is a promising adjunctive treatment for pancreatic carcinoma.
  • [MeSH-minor] 3' Untranslated Regions. 5' Untranslated Regions. Animals. Apoptosis / genetics. Blotting, Western. Cell Line, Tumor. Cells, Cultured. Humans. Kidney / metabolism. Liver / metabolism. Male. Mice. Mice, Nude. Neoplasm Transplantation. Polymerase Chain Reaction / methods. Transplantation, Heterologous


8. Dubin RF, Robinson SK, Widdicombe JH: Secretion of lactoferrin and lysozyme by cultures of human airway epithelium. Am J Physiol Lung Cell Mol Physiol; 2004 Apr;286(4):L750-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we compared release of these compounds from the following human cell cultures: primary cultures of tracheal epithelium (HTE), Calu-3 cells (a lung adenocarcinoma cell line frequently used as a model of serous gland cells), 16HBE14o- cells (an SV40 transformed line from airway surface epithelium), T84 cells (a colon carcinoma cell line), and human foreskin fibroblasts (HFF).
  • For lysozyme, baseline secretory rates were in the order Calu-3 > 16HBE14o- > HTE T84 > HFF = 0; for lactoferrin, the only cell type showing measurable release was HTE; for mucus, HTE > Calu-3 > 16HBE14o- T84 > HFF = 0.
  • A wide variety of neurohumoral agents and inflammatory stimuli was without effect on lactoferrin and lysozyme release from HTE or Calu-3 cells, although forskolin did stimulate secretion of water and lysozyme from Calu-3 cells.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15003937.001).
  • [ISSN] 1040-0605
  • [Journal-full-title] American journal of physiology. Lung cellular and molecular physiology
  • [ISO-abbreviation] Am. J. Physiol. Lung Cell Mol. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.1.17 / Muramidase; EC 3.4.21.- / Lactoferrin
  •  go-up   go-down


9. Bair EL, Massey CP, Tran NL, Borchers AH, Heimark RL, Cress AE, Bowden GT: Integrin- and cadherin-mediated induction of the matrix metalloprotease matrilysin in cocultures of malignant oral squamous cell carcinoma cells and dermal fibroblasts. Exp Cell Res; 2001 Nov 1;270(2):259-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrin- and cadherin-mediated induction of the matrix metalloprotease matrilysin in cocultures of malignant oral squamous cell carcinoma cells and dermal fibroblasts.
  • Here, we show that an oral squamous cell carcinoma cell line (SCC-25) expresses low levels of promatrilysin when cultured alone.
  • However, when SCC-25 cells are cocultured with human foreskin fibroblasts (HFF), there is a 40-fold induction of promatrilysin expression.
  • Our results are of general interest in relation to the regulation of MMP expression through cell surface receptor regulation.
  • [MeSH-major] Antigens, CD29 / metabolism. Cadherins / metabolism. Carcinoma, Squamous Cell. Dermis / cytology. Matrix Metalloproteinase 7 / genetics. Mouth Neoplasms
  • [MeSH-minor] Blotting, Western. Calcium / metabolism. Cell Communication / physiology. Chelating Agents / pharmacology. Coculture Techniques. Egtazic Acid / pharmacology. Enzyme Precursors / genetics. Extracellular Matrix / physiology. Fibroblasts / cytology. Fibroblasts / secretion. Gene Expression Regulation, Enzymologic / drug effects. Gene Expression Regulation, Enzymologic / physiology. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / physiology. Humans. Metalloendopeptidases / genetics. Peptides / pharmacology. Tumor Cells, Cultured


10. Ocker M, Herold C, Ganslmayer M, Hahn EG, Schuppan D: The synthetic retinoid adapalene inhibits proliferation and induces apoptosis in colorectal cancer cells in vitro. Int J Cancer; 2003 Nov 10;107(3):453-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chemotherapy of advanced stages of colorectal carcinoma is unsatisfactory.
  • We compared the effect of the synthetic retinoid adapalene (ADA) and 9-cis-retinoic acid (CRA) on carcinoma cell lines in vitro.
  • Colon carcinoma cell lines CC-531, HT-29 and LOVO as well as human foreskin fibroblasts were exposed to different concentrations of ADA and CRA for 3-72 hr.
  • Therefore, we suggest that ADA may be far more suitable as an adjunctive therapeutic agent for treatment of colon cancer in vivo.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Colorectal Neoplasms / drug therapy. Naphthalenes / pharmacology
  • [MeSH-minor] Adapalene. Caspase 3. Caspases / metabolism. Cell Division / drug effects. Humans. Proto-Oncogene Proteins / physiology. Proto-Oncogene Proteins c-bcl-2 / physiology. Tretinoin / pharmacology. Tumor Cells, Cultured. bcl-2-Associated X Protein

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. ALITRETINOIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 14506747.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BAX protein, human; 0 / Naphthalenes; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 1L4806J2QF / Adapalene; 5300-03-8 / alitretinoin; 5688UTC01R / Tretinoin; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


11. Singh R, Lei P, Andreadis ST: PKC-delta binds to E-cadherin and mediates EGF-induced cell scattering. Exp Cell Res; 2009 Oct 15;315(17):2899-913
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Amino Acid Substitution. Calcium-Calmodulin-Dependent Protein Kinases / antagonists & inhibitors. Carcinoma, Squamous Cell. Cell Adhesion / drug effects. Cell Adhesion / physiology. Cell Line, Tumor. Enzyme Inhibitors / pharmacology. Flavonoids / pharmacology. Foreskin / cytology. Foreskin / physiology. Humans. Imidazoles / pharmacology. Infant, Newborn. Keratinocytes / cytology. Keratinocytes / physiology. Kidney / embryology. Male. Pyridines / pharmacology. RNA, Small Interfering / genetics. Receptor, Epidermal Growth Factor / drug effects. Receptor, Epidermal Growth Factor / genetics. Tight Junctions / drug effects. Tight Junctions / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19591825.001).
  • [ISSN] 1090-2422
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB000876
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Cadherins; 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / Imidazoles; 0 / Pyridines; 0 / RNA, Small Interfering; 0 / SB 203580; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.13 / Protein Kinase C-delta; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  •  go-up   go-down


12. Rincon-Orozco B, Halec G, Rosenberger S, Muschik D, Nindl I, Bachmann A, Ritter TM, Dondog B, Ly R, Bosch FX, Zawatzky R, Rösl F: Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells. Cancer Res; 2009 Nov 15;69(22):8718-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells.
  • We have investigated interferon-kappa (IFN-kappa) regulation in the context of human papillomavirus (HPV)-induced carcinogenesis using primary human foreskin keratinocytes (HFK), immortalized HFKs encoding individual oncoproteins of HPV16 (E6, E7, and E6/E7), and cervical carcinoma cells.
  • Transcription could be reactivated after DNA demethylation but was decreased again upon drug removal.
  • Partial reactivation could also be accomplished when E6 was knocked down, suggesting a contribution of E6 in IFN-kappa de novo methylation.
  • To prove the functional relevance of IFN-kappa in building up an antiviral response, IFN-kappa was ectopically expressed in cervical carcinoma cells where protection against vesicular stomatitis virus-mediated cytolysis could be achieved.
  • This is the first report showing an epigenetic silencing of type I IFN after HPV16 oncogene expression and revealing a novel strategy on how high-risk HPVs can abolish the innate immune response in their genuine host cells.
  • [MeSH-major] Gene Expression Regulation. Gene Silencing / physiology. Interferon Type I / genetics. Papillomavirus Infections / genetics. Signal Transduction / physiology
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. CpG Islands. DNA Methylation. Down-Regulation. Female. Gene Expression. Human papillomavirus 16 / immunology. Humans. Keratinocytes / virology. Oncogene Proteins, Viral / biosynthesis. Oncogene Proteins, Viral / genetics. RNA, Small Interfering. Repressor Proteins / biosynthesis. Repressor Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction. Transcription, Genetic. Tumor Suppressor Protein p53 / metabolism. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / virology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19887612.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / E6 protein, Human papillomavirus type 16; 0 / Interferon Type I; 0 / Oncogene Proteins, Viral; 0 / RNA, Small Interfering; 0 / Repressor Proteins; 0 / Tumor Suppressor Protein p53; 0 / interferon kappa
  •  go-up   go-down


13. Morrison JA, Raab-Traub N: Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of {beta}-catenin signaling. J Virol; 2005 Feb;79(4):2375-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, the biological consequences of LMP2A expression in the normal human foreskin keratinocyte (HFK) cell line were investigated and the importance of the ITAM and PY motifs for LMP2A signaling effects in HFK cells was ascertained.
  • LMP2A is expressed in the EBV-associated epithelial malignancies nasopharyngeal carcinoma and gastric carcinoma, and these data indicate that LMP2A affects cellular processes that likely contribute to carcinogenesis.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Infect Agents Dis. 1994 Apr-Jun;3(2-3):128-36 [7812651.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5522-7 [10318916.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Aug;19(4):201-14 [9258654.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1664-72 [9269787.001]
  • [Cites] J Virol. 2000 Feb;74(3):1101-13 [10627520.001]
  • [Cites] Virology. 2000 Mar 1;268(1):178-91 [10683340.001]
  • [Cites] Biochem J. 2000 Mar 15;346 Pt 3:561-76 [10698680.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1537-47 [10793065.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] J Virol. 2000 Oct;74(19):9115-24 [10982358.001]
  • [Cites] J Virol. 2000 Nov;74(22):10681-9 [11044112.001]
  • [Cites] J Virol. 2000 Nov;74(22):10838-45 [11044134.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(22):8526-35 [11046148.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):255-61 [11091849.001]
  • [Cites] Virology. 1997 Sep 1;235(2):241-51 [9281504.001]
  • [Cites] EMBO J. 1997 Nov 3;16(21):6325-36 [9351815.001]
  • [Cites] J Virol. 2001 Jun;75(12):5711-8 [11356981.001]
  • [Cites] Trends Biochem Sci. 2001 Nov;26(11):657-64 [11701324.001]
  • [Cites] Am J Pathol. 2002 Feb;160(2):389-401 [11839557.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] J Virol. 2003 Nov;77(22):12276-84 [14581564.001]
  • [Cites] Oncogene. 2004 Mar 15;23(11):1972-84 [15021885.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 11;1697(1-2):3-16 [15023346.001]
  • [Cites] Cell. 1986 Dec 26;47(6):883-9 [3022942.001]
  • [Cites] J Cell Biol. 1988 Mar;106(3):761-71 [2450098.001]
  • [Cites] J Virol. 1992 May;66(5):2689-97 [1313894.001]
  • [Cites] J Virol. 1992 May;66(5):3257-62 [1313931.001]
  • [Cites] J Virol. 1993 Jun;67(6):3087-94 [7684459.001]
  • [Cites] Carcinogenesis. 1993 May;14(5):833-9 [8504475.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):772-6 [8290598.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Immunity. 1998 Sep;9(3):405-11 [9768760.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Immunity. 1995 Feb;2(2):155-66 [7895172.001]
  • (PMID = 15681438.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA032979; United States / NCI NIH HHS / CA / R01 CA103634; United States / NCI NIH HHS / CA / CA103634; United States / NCI NIH HHS / CA / CA32979
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Trans-Activators; 0 / Viral Matrix Proteins; 0 / beta Catenin
  • [Other-IDs] NLM/ PMC546559
  •  go-up   go-down


14. Schobert R, Biersack B, Knauer S, Ocker M: Conjugates of the fungal cytotoxin illudin M with improved tumour specificity. Bioorg Med Chem; 2008 Sep 15;16(18):8592-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Esters of illudin M with docosahexaenoic acid, chlorambucil, demethylcantharidinic acid (endothall) and 2,2'-bipyridyl-5,5'-dicarboxylic acid were synthesised and tested for cytotoxicity and induction of apoptosis in two clinically relevant tumour cell lines (Panc-1 pancreas carcinoma and HT-29 colon carcinoma) and in non-malignant human foreskin fibroblasts.
  • [MeSH-major] Agaricales / metabolism. Cytotoxins / pharmacology. Esters / pharmacology. Fibroblasts / drug effects
  • [MeSH-minor] Cell Line, Tumor / drug effects. Chlorambucil / chemistry. Chlorambucil / pharmacology. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Dicarboxylic Acids / chemistry. Dicarboxylic Acids / pharmacology. Docosahexaenoic Acids / chemistry. Docosahexaenoic Acids / pharmacology. Humans. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Sesquiterpenes / chemistry. Sesquiterpenes / isolation & purification. Sesquiterpenes / pharmacology. Structure-Activity Relationship. Toxicity Tests

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ENDOTHALL .
  • Hazardous Substances Data Bank. DIPOTASSIUM ENDOTHALL .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18715789.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytotoxins; 0 / Dicarboxylic Acids; 0 / Esters; 0 / Sesquiterpenes; 1146-04-9 / illudin M; 145-73-3 / endothall; 18D0SL7309 / Chlorambucil; 25167-62-8 / Docosahexaenoic Acids
  •  go-up   go-down


15. Effenberger K, Breyer S, Schobert R: Terpene conjugates of the Nigella sativa seed-oil constituent thymoquinone with enhanced efficacy in cancer cells. Chem Biodivers; 2010 Jan;7(1):129-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Derivatives bearing terpene-terminated 6-alkyl residues were tested in cells of human HL-60 leukemia, 518A2 melanoma, multidrug-resistant KB-V1/Vbl cervix, and MCF-7/Topo breast carcinomas, as well as in non-malignant human foreskin fibroblasts.
  • It was seven times more active than TQ (1) in 518A2 melanoma cells and four times in KB-V1/Vbl cervix carcinoma cells, while only half as toxic in the fibroblasts.
  • Compound 3a was also not a substrate for the P-gp and BCRP drug transporters of the resistant cancer cells.
  • The caryophyllyl and germacryl conjugates 3e and 3f specifically inhibited the growth of the resistant MCF-7 breast carcinoma cells.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / chemistry. Benzoquinones / chemistry. Nigella sativa / chemistry. Terpenes / chemistry
  • [MeSH-minor] Cell Line, Tumor. Drug Screening Assays, Antitumor. HL-60 Cells. Humans. Membrane Potential, Mitochondrial / drug effects. Oils, Volatile / chemistry. Seeds / chemistry

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087986.001).
  • [ISSN] 1612-1880
  • [Journal-full-title] Chemistry & biodiversity
  • [ISO-abbreviation] Chem. Biodivers.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Benzoquinones; 0 / Oils, Volatile; 0 / Terpenes; 490-91-5 / thymoquinone
  •  go-up   go-down


16. Poindexter G, Morrell DS: Anogenital pruritus: lichen sclerosus in children. Pediatr Ann; 2007 Dec;36(12):785-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Females present with vulvar itching, soreness, dysuria, or gastrointestinal complaints, while males tend to have difficulty retracting the foreskin leading to phimosis.
  • LS in children has been commonly misdiagnosed as sexual abuse, leading to delay in appropriate diagnosis and unnecessary turmoil for families.
  • There is a significant risk of squamous cell carcinoma developing in genital LS in adults possibly from chronic inflammation, delay in diagnosis, and delay in appropriate treatment.
  • The risk of squamous cell carcinoma in pediatric onset LS is undefined.
  • It is also unclear if effective control of cutaneous inflammation can decrease the risk of malignant transformation.
  • [MeSH-minor] Autoimmune Diseases / complications. Carcinoma, Squamous Cell / etiology. Child. Diagnosis, Differential. Female. Genital Diseases, Male / complications. Genital Diseases, Male / diagnosis. Genital Diseases, Male / drug therapy. Humans. Immunosuppressive Agents / administration & dosage. Infant. Male. Prognosis. Risk Factors

  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - Itching.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18229519.001).
  • [ISSN] 0090-4481
  • [Journal-full-title] Pediatric annals
  • [ISO-abbreviation] Pediatr Ann
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 39
  •  go-up   go-down


17. Mallon E, Hawkins D, Dinneen M, Francics N, Fearfield L, Newson R, Bunker C: Circumcision and genital dermatoses. Arch Dermatol; 2000 Mar;136(3):350-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: It is well recognized that the presence of a foreskin predisposes to penile carcinoma and sexually transmitted infections.
  • We have investigated the relationship between the presence or absence of the foreskin and penile dermatoses.
  • OBJECTIVE: To determine whether there is an association between circumcision and penile dermatoses.
  • SUBJECTS: The study population consisted of 357 male patients referred for diagnosis and management of genital skin disease.
  • The control population consisted of 305 male patients without genital skin disease attending the general dermatology clinics over a 4-month period.
  • The rate of circumcision in the general male dermatology population was determined.
  • RESULTS: The most common diagnoses were psoriasis (n = 94), penile infections (n = 58), lichen sclerosus (n = 52), lichen planus (n = 39), seborrheic dermatitis (n = 29), and Zoon balanitis (n = 27).
  • Less common diagnoses included squamous cell carcinoma (n = 4), bowenoid papulosis (n = 3), and Bowen disease (n = 3).
  • The age-adjusted odds ratio for all penile skin diseases associated with presence of the foreskin was 3.24 (95% confidence interval, 2.26-4.64).
  • The majority of men with penile infections (84%) were uncircumcised.
  • The presence of the foreskin may promote inflammation by a köebnerization phenomenon, or the presence of infectious agents, as yet unidentified, may induce inflammation.
  • The data suggest that circumcision prevents or protects against common infective penile dermatoses.

  • MedlinePlus Health Information. consumer health - Circumcision.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2001 Apr;137(4):503-4 [11295938.001]
  • (PMID = 10724196.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


18. Gatto-Weis C, Topolsky D, Sloane B, Hou JS, Qu H, Fyfe BS: Ulcerative balanoposthitis of the foreskin as a manifestation of chronic lymphocytic leukemia: case report and review of the literature. Urology; 2000 Oct 1;56(4):669
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ulcerative balanoposthitis of the foreskin as a manifestation of chronic lymphocytic leukemia: case report and review of the literature.
  • Ulcerative lesions of the penis have many possible etiologies, including infectious, neoplastic, traumatic, drug-induced, and autoimmune.
  • Although the most frequent neoplasm presenting as an ulcerative penile lesion is squamous cell carcinoma, it may rarely be a manifestation of other malignancies, including those of hematolymphoid origin.
  • Chronic lymphocytic leukemia and other hematolymphoid malignancies should be considered in the large differential diagnosis of nonhealing penile ulcers.


19. Okamoto K, Ocker M, Neureiter D, Dietze O, Zopf S, Hahn EG, Herold C: bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells. J Cell Mol Med; 2007 Mar-Apr;11(2):349-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We therefore investigated if and to what extend silencing of bcl-2 by specific siRNAs (siBCL2) might enhance Gemcitabine effects in human pancreatic carcinoma cells. siBCL2 was transfected into the pancreatic cancer cell line YAP C alone and 72 hrs before co-incubation with different concentrations of Gemcitabine.
  • In contrast, non-transformed human foreskin fibroblasts showed only minor responses to this treatment.
  • [MeSH-minor] Adenocarcinoma / pathology. Cell Line, Tumor. Dose-Response Relationship, Drug. Humans. Time Factors. Transfection

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 2.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378914.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / RNA, Small Interfering; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Other-IDs] NLM/ PMC3822833
  •  go-up   go-down


20. Gahr S, Peter G, Wissniowski TT, Hahn EG, Herold C, Ocker M: The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines. Oncol Rep; 2008 Nov;20(5):1249-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Effective therapies for advanced stages of hepatocellular carcinoma (HCC) have yet to be developed.
  • Human hepatoma cell lines Hep3B and HepG2 as well as primary human foreskin fibroblasts as non-malignant controls were cultured under standardized conditions and incubated with increasing concentrations of CYC-202 and MS-275 as single agents and in combination.
  • [MeSH-major] Benzamides / pharmacology. Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Purines / pharmacology. Pyridines / pharmacology
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Blotting, Western. Caspase 3 / drug effects. Caspase 8 / drug effects. Cell Line, Tumor. Enzyme Inhibitors / pharmacology. Flow Cytometry. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949429.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Enzyme Inhibitors; 0 / Purines; 0 / Pyridines; 0 / roscovitine; 1ZNY4FKK9H / entinostat; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8
  •  go-up   go-down


21. Kotchetkov R, Cinatl J, Krivtchik AA, Vogel JU, Matousek J, Pouckova P, Kornhuber B, Schwabe D, Cinatl J Jr: Selective activity of BS-RNase against anaplastic thyroid cancer. Anticancer Res; 2001 Mar-Apr;21(2A):1035-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Anaplastic thyroid carcinoma is an aggressive solid tumor that fails to adequately respond to any known chemotherapeutic regimen.
  • The development of effective chemotherapy agents would provide the best chance for long-term survival of patients.
  • MATERIALS AND METHODS: The cytotoxic effects of bovine seminal ribonuclease (BS-RNase) against thyroid carcinoma cell lines with different degrees of differentiation in comparison to non-malignant cells, including human foreskin fibroblasts (HFF) and retinal pigment epithelial cells (RPE), were tested using the MTT dye reduction assay.
  • Induction of apoptosis was demonstrated by annexin V assay and expression of proteins related to apoptosis was investigated by flow cytometry.
  • The antitumoral in vivo effects of BS-RNase were assessed on established xenografts of anaplastic thyroid carcinoma cell line 8505C in nude mice using subcutaneous injections of BS-RNase (12.5 mg/kg once a day, on 20 consecutive days).
  • The greatest growth inhibition was seen in the 8505C line, while IC50 values for papillary (B-CPAP) and poorly-differentiated thyroid carcinoma cells were about 6-fold higher.
  • No apparent toxic effects of BS-RNase toward non-malignant cells were observed during the in vivo treatment.
  • After cessation of therapy (day 20) tumor volume continued to decrease and the tumor was no longer detectable after 30 days of treatment induction in all animals.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endoribonucleases / therapeutic use. Thyroid Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antigens, CD95 / biosynthesis. Apoptosis. Cattle. Fas Ligand Protein. Female. Humans. Membrane Glycoproteins / biosynthesis. Mice. Mice, Nude. Neoplasm Transplantation. Neoplasms, Experimental. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11396137.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Antineoplastic Agents; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Fasl protein, mouse; 0 / Membrane Glycoproteins; 0 / Proto-Oncogene Proteins c-bcl-2; EC 3.1.- / Endoribonucleases; EC 3.1.27.- / ribonuclease SPL
  •  go-up   go-down






Advertisement